The Marketing Authorisation Application (MAA) for CT001 is submitted to the European Medicines Agency (EMA) for acute pain management in children ... CT001 is being developed for acute pain management in ...
“I realized that although we are very good at treating acute pain, it's almost impossible to treat chronic pain,” he said ... studies cellular and molecular mechanisms of acute and chronic pain.
The acute pain market is rapidly evolving, driven by the increasing demand for non-opioid pain management solutions amidst growing concerns over the opioid crisis ... The acute pain market is rapidly ...